NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading KRMD? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a cautious view on a company that is currently loss-making. The thesis is in a watch state, reflecting concerns about recent weak financial performance and elevated risks, while also considering sector tailwinds.
The market seems to have priced in a justified valuation with a low expectations gap. There is a durable premium compared to peers, indicating that investors are aware of the company's challenges but still see some potential.
Management aims to achieve positive adjusted EBITDA and cash flow in 2026, but progress has been mixed. Revenue growth is on track, but overall financial performance remains weak, which poses risks in the near term.
The long-term thesis hinges on management's ability to meet their financial targets and the performance of sector bellwethers. If larger companies in the healthcare sector continue to perform well, it could provide a boost to KRMD.
In the next 1-3 years, KRMD's performance will depend on execution and sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This would indicate KORU Medical is struggling to meet its annual growth target.
Confirms:Q2 2026 revenue growth reported below 15% year over year.
Disproves:Q2 2026 revenue growth reported at or above 15% year over year.
Why it matters: New M&A activity could enhance KORU's market position and growth potential. It may attract investor interest.
Confirms:Announcement of a new M&A deal or partnership.
Disproves:No new M&A activity or negative news regarding previous deals.
Why it matters: Faster growth in healthcare could help KORU Medical do better.
Confirms:The healthcare sector is showing revenue growth going back to 10% or more.
Disproves:Healthcare sector revenue growth keeps slowing down below current levels.
Why it matters: The earnings report will show if KORU Medical can improve its loss-making status.
Confirms one read:Earnings report shows a reduction in losses compared to the previous quarter.
Confirms the other:Earnings report shows losses increasing or staying the same compared to the previous quarter.
Why it matters: This agreement could change KORU's supply chain and how much it can produce.
Confirms one read:They announced that the M&A agreement was successfully put into action.
Confirms the other:News of delays or issues with the M&A agreement.
Why it matters: If it drops below this level, costs may rise and hurt profits.
Confirms:Gross margin reported below 61% in Q2 2026.
Disproves:Gross margin reported at or above 61% in Q2 2026.
Why it matters: Progress in these trials could enhance KORU's market position and revenue potential.
Confirms:There was an announcement of successful results from the Phase III trials.
Disproves:Delays or setbacks reported in the Phase III trials.
